Research article summary (published 30 Oct 2009):

Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats.

Full Abstract

BACKGROUND: Chemoprevention utilizing dietary agents is an effective means to slow the development of prostate cancer. We evaluated the potential additive and synergistic effects of genistein and resveratrol for suppressing prostate cancer in the Simian Virus-40 T-antigen (SV-40 Tag) targeted probasin promoter rat model, a transgenic model of spontaneously developing prostate cancer. METHODS: Rats were fed genistein or resveratrol (250 mg/kg AIN-76A diet) alone and in combination, and a low-dose combination (83 mg genistein + 83 mg resveratrol/kg diet). Histopathology and mechanisms of action studies were conducted at 30 and 12 weeks of age, respectively. RESULTS: Genistein, resveratrol, and the high-dose combination treatments suppressed prostate cancer. The low-dose combination did not elicit protection against prostate cancer and was most likely below the effective dose for causing significant histopathological changes. Total genistein and resveratrol concentrations in the blood reached 2,160 and 211 nM, respectively in rats exposed to the single treatments. Polyphenol treatments decreased cell proliferation and insulin-like growth factor-1 (IGF-1) protein expression in the prostate. In addition, genistein as a single agent induced apoptosis and decreased steroid receptor coactivator-3 (SRC-3) in the ventral prostate (VP). CONCLUSIONS: Genistein and resveratrol, alone and in combination, suppress prostate cancer development in the SV-40 Tag model. Regulation of SRC-3 and growth factor signaling proteins are consistent with these nutritional polyphenols reducing cell proliferation and increasing apoptosis in the prostate.

Author information

Author/s: Harper, Curt E (CE); Cook, Leah M (LM); Patel, Brijesh B (BB); Wang, Jun (J); Eltoum, Isam A (IA); Arabshahi, Ali (A); Shirai, Tomoyuki (T); Lamartiniere, Coral A (CA);

Affiliation: Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

Grants: CA 47888 (Agency:NCI NIH HHS) ; P30 CA-13148-34 (Agency:NCI NIH HHS) ; U54 CA100949-010002 (Agency:NCI NIH HHS) ; U54-CA10094 (Agency:NCI NIH HHS)

Journal and publication information

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal: The Prostate (Prostate), published in United States. (Language: eng)

Reference: 2009-Nov; vol 69 (issue 15) : pp 1668-82

Dates: Created 2009/09/28; Completed 2009/10/15; Revised 2009/11/03;

PMID: 19670229, status: MEDLINE (last retrieval date: 11/4/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Administration, Oral Animals Anticarcinogenic Agents - pharmacology Antigens, Polyomavirus Transforming - biosynthesis; genetics Apoptosis - drug effects Cell Growth Processes - drug effects Genistein - blood; pharmacology Histone Acetyltransferases - metabolism Immunohistochemistry

Insulin-Like Growth Factor I - metabolism Ki-67 Antigen - metabolism Male Prostatic Neoplasms - metabolism; pathology; prevention & control Rats Rats, Sprague-Dawley Rats, Transgenic Stilbenes - blood; pharmacology Trans-Activators - metabolism

Associated Chemicals: Anticarcinogenic Agents (0) ; Antigens, Polyomavirus Transforming (0) ; Ki-67 Antigen (0) ; Stilbenes (0) ; Trans-Activators (0) ; Genistein (446-72-0) ; resveratrol (501-36-0) ; Insulin-Like Growth Factor I (67763-96-6) ; Histone Acetyltransferases (EC 2.3.1.48) ; nuclear receptor coactivator 3 (EC 2.3.1.48)

Related articles

These are the highest related articles currently in the database:

• Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. 24 Jun 2008
• Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. 30 Jul 2002
• Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. 30 Dec 1997
• 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. 13 Oct 2001
• Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. 13 Sep 1998
• Anticancer activity of genistein on implanted tumor of human SG7901 cells in nude mice. 26 Jan 2008
• Chemoprotective action of resveratrol and genistein from apoptosis induced in human peripheral blood lymphocytes. 30 Jan 2008
• Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression. 30 Aug 2008
• Apoptotic activity of genistein on human lung adenocarcinoma SPC-A-1 cells and preliminary exploration of its mechanisms using microarray. 27 Jan 2008
• Nanomolar level of resveratrol (trans-3,5,4'-trihydroxystilbene) is required, but is not sufficient, to inhibit the growth of human monocytoid tumor cells through an apoptotic-like mechanism. 30 Dec 2001

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.